Krystal Biotech(NASDAQ) KRYS

Krystal Biotech, Inc. makes medicines that fix genetic mistakes in the body. These therapies help people with rare skin and lung diseases heal. Patients can use these treatments at home or in a clinic.

Treatments for Rare Genetic Conditions

• VYJUVEK: Topical gene therapy for dystrophic epidermolysis bullosa; accounted for all product revenue for the three-month period ended June 30, 2026.
• Ophthalmology: Redosable eye drop formulations designed to treat corneal complications and rare degenerative eye diseases.
• Respiratory: Inhaled gene therapies delivered via nebulizer for the treatment of cystic fibrosis and lung protein deficiencies.
• Oncology: Immunotherapies designed to promote immune-mediated tumor clearance through direct injection or inhalation into the lungs.
• Jeune Aesthetics: Subsidiary developing gene therapies to address skin aging and elasticity loss.

Expanding Across the Globe

• Launched VYJUVEK in the United States in 2023 following approval by the Food and Drug Administration.
• Expanded commercial operations into Germany, France, and Japan during 2025.
• Received approval for VYJUVEK in the United Kingdom in May 2026.
• Secured platform technology designations from the Food and Drug Administration for multiple pipeline candidates to streamline development.
• Advanced inhaled KB707 into phase 1/2 clinical trials for patients with lung cancer.

What Sets the Platform Apart

The company uses a proprietary platform based on modified herpes simplex virus type 1 to deliver genes to multiple organ systems. This technology allows for non-invasive applications, such as gels and inhaled mists, that can be used at home.

By the Numbers

• Product revenue reached $119.2 million for the three-month period ended June 30, 2026, up 24% year over year.
• Net income was $54.8 million for the three-month period ended June 30, 2026, up 43% year over year.
• Gross margin reached 95% for the three-month period ended June 30, 2026.
• Cumulative net product revenue since the first 2023 launch totaled $965.9 million as of June 30, 2026.
• Cash, cash equivalents, and short-term investments totaled $845.6 million as of June 30, 2026.

Bottom Line

Krystal Biotech has evolved from a clinical-stage research firm into a global commercial organization with a high-margin lead product. Its flexible genetic platform and in-house manufacturing capabilities support a broad pipeline across dermatology, ophthalmology, and respiratory medicine.